Qualigen Therapeutics Inc (QLGN): Price and Financial Metrics

Qualigen Therapeutics Inc (QLGN): $0.51

0.03 (+6.87%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add QLGN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#173 of 426

in industry

QLGN Price/Volume Stats

Current price $0.51 52-week high $1.38
Prev. close $0.47 52-week low $0.45
Day low $0.47 Volume 131,500
Day high $0.51 Avg. volume 46,688
50-day MA $0.54 Dividend yield N/A
200-day MA $0.85 Market Cap 2.63M

QLGN Stock Price Chart Interactive Chart >

QLGN Stock Summary

  • QLGN has a market capitalization of $2,828,858 -- more than approximately just 1.44% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for QLGN is -2.82 -- better than just 4% of US stocks.
  • With a year-over-year growth in debt of -66.78%, QUALIGEN THERAPEUTICS INC's debt growth rate surpasses merely 2.93% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to QUALIGEN THERAPEUTICS INC, a group of peers worth examining would be COHU, SMSI, CYCN, BFLY, and MRCY.
  • QLGN's SEC filings can be seen here. And to visit QUALIGEN THERAPEUTICS INC's official web site, go to www.qualigeninc.com.

QLGN Valuation Summary

  • In comparison to the median Healthcare stock, QLGN's price/sales ratio is 85.71% lower, now standing at 0.6.
  • QLGN's price/sales ratio has moved NA NA over the prior 104 months.

Below are key valuation metrics over time for QLGN.

Stock Date P/S P/B P/E EV/EBIT
QLGN 2023-12-29 0.6 -1.7 -0.2 -0.1
QLGN 2023-12-28 0.6 -1.8 -0.2 -0.1
QLGN 2023-12-27 0.6 -1.8 -0.2 -0.1
QLGN 2023-12-26 0.6 -1.8 -0.2 -0.1
QLGN 2023-12-22 0.6 -1.8 -0.2 -0.1
QLGN 2023-12-21 0.7 -1.9 -0.2 -0.1

QLGN Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 16.9%.
  • Its 4 year cash and equivalents growth rate is now at 16.9%.
  • Its 4 year net cashflow from operations growth rate is now at 40.82%.
Over the past 33 months, QLGN's revenue has gone up $5,074,857.

The table below shows QLGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 5.074857 -13.92315 -18.32906
2022-06-30 4.788857 -13.77348 -17.36247
2022-03-31 4.476258 -16.53125 -18.5443
2021-12-31 5.653725 -14.73074 -17.89714
2021-09-30 5.280276 -15.27428 -4.690626
2021-06-30 4.962925 -16.7582 -9.945321

QLGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QLGN has a Quality Grade of C, ranking ahead of 42.69% of graded US stocks.
  • QLGN's asset turnover comes in at 0.208 -- ranking 197th of 681 Pharmaceutical Products stocks.
  • XBIT, AYTU, and QDEL are the stocks whose asset turnover ratios are most correlated with QLGN.

The table below shows QLGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.208 0.204 1.367
2021-03-31 0.226 0.191 2.289
2020-12-31 0.350 0.187 2.195
2020-09-30 0.179 0.007 3.635
2020-06-30 0.172 0.106 5.369
2020-03-31 0.000 NA 5.491

QLGN Price Target

For more insight on analysts targets of QLGN, see our QLGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.75 Average Broker Recommendation 1.5 (Moderate Buy)

Qualigen Therapeutics Inc (QLGN) Company Bio


Qualigen Therapeutics Inc operates as a biotech company. The Company develops and discovers novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics serves customers in the State of California.


QLGN Latest News Stream


Event/Time News Detail
Loading, please wait...

QLGN Latest Social Stream


Loading social stream, please wait...

View Full QLGN Social Stream

Latest QLGN News From Around the Web

Below are the latest news stories about QUALIGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate QLGN as an investment opportunity.

QLGN: Dosing Begins in Phase 1 Trial of QN-302…

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Dosing Begins in Phase 1 Trial of QN-302 On November 7, 2023, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced that the first three patients have begun dosing in the Phase 1a clinical trial of QN-302. This is a multicenter, open label, dose escalation, and dose expansion trial evaluating the safety,

Yahoo | November 27, 2023

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024 CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics co

Yahoo | November 14, 2023

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

CARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumo

Yahoo | November 7, 2023

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breas

Yahoo | October 23, 2023

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1 Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces t

Yahoo | September 27, 2023

Read More 'QLGN' Stories Here

QLGN Price Returns

1-mo 3.45%
3-mo N/A
6-mo -49.83%
1-year -58.20%
3-year -98.72%
5-year -99.67%
YTD -7.27%
2023 -57.33%
2022 -87.95%
2021 -64.45%
2020 -28.72%
2019 -71.85%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!